权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A GFP-based HTS Assay for HIV-1 Reactivating Agents

基于 GFP 的 HIV-1 重新激活剂 HTS 测定

基本信息

批准号：
7225977
负责人：
OLAF KUTSCH
金额：
$ 31.04万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-04-01 至 2009-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7225977
关键词：
Advanced Development Alabama Allogenic Biological Assay Body Burden Cell Line Cell Survival Cells Characteristics Clinical Development Disease Drug Design Evaluation Fluorescence Future Generations Genes Goals HIV-1 Human In Vitro Infection Institution Interleukin-2 Introns Joints Kinetics Lead Libraries Lymphoid Cell Molecular Target Molecular Virology Monoclonal Antibodies Monoclonal Antibody HuM291 Muromonab-CD3 Numbers Patients Pharmaceutical Preparations Preclinical Drug Evaluation Process Proteins Protocols documentation Proviruses Ramp Range Reader Reading Reporter Reproducibility Research Research Institute Research Personnel Rest Robotics Screening procedure Site System T memory cell T-Cell Activation T-Lymphocyte Testing Therapeutic Therapeutic Agents Treatment Protocols Universities Validation Viral Work base drug discovery enhanced green fluorescent protein high throughput screening in vivo memory CD4 T lymphocyte novel pre-clinical programs scale up small molecule small molecule libraries

项目摘要

DESCRIPTION (provided by applicant): HIV-1 latency is a major obstacle to effective, lifelong control of HIV-1 infection and has been the nemesis of curative strategies for the disease. Remarkably, estimates of the total body burden of latently-infected cells are in the range of only 106, a notably small number that would seem to represent a tractable target, nonetheless, previous attempts to eliminate these latently-infected cells using anti-CD3 monoclonal antibodies or Interleukin 2 (II-2)) have been unsuccessful. In this application, we propose a joint research effort between the University of Alabama at Birmingham and the Southern Research Institute (SRI) focusing on the discovery and validation of novel small molecule drug candidates that selectively activate HIV-1 expression in lymphoid cells. The proposed research builds on a body of previous work by SRI investigators and by our group (J Virol. 76:8776, 2002) that both demonstrates feasibility of the project and provides the critical cell-based assays needed for immediate ramp-up to high throughput screening (HTS) of compound libraries. Specific aims are: (i) to transfer an existing latently HIV-1 infected reporter cell line that uses enhanced green fluorescent protein as a quantitative marker of HIV-1 expression and is amenable to HTS in a 384-well plate format to the fully automated HTS platform at the SRI; (ii) to perform assay validation and initial screens of >1,000 compounds for activity in inducing HIV-1 expression; (iii) to generate second generation HIV-1 latency assays that will minimize false negative or positive hits; (iv) to develop protocols that allow for the evaluation of the ability of lead compounds identified by HTS to induce HIV-1 expression in virally-infected CD4+ memory T lymphocytes from HIV-infected patients. The proposed research capitalizes on unique and proven strengths at DAB and SRI in molecular virology and drug discovery and promises to provide a scientific and technical platform that will allow for the future screening of large compound libraries with the objective to discover and preclinically develop HIV-1 reactivating agents. Integration of HIV-1 reactivating agents into the existing HIV-1 treatment schedule with the goal to deplete the cellular reservoirs of latent HIV-1 will be a first essential step towards the development of a therapeutic treatment strategy for HIV-1 infection.

描述（由申请人提供）：